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Abstract Monoamine oxidase B (MAO B) is an outer mito-
chondrial membrane protein that oxidizes arylalkylamine neuro-
transmitters and has been a valuable drug target for many neu-
rological disorders. The 1.7 A# resolution structure of human
MAO B shows the enzyme is dimeric with a C-terminal trans-
membrane helix protruding from each monomer and anchoring
the protein to the membrane. This helix departs perpendicularly
from the base of the structure in a di¡erent way with respect to
other monotopic membrane proteins. Several apolar loops ex-
posed on the protein surface are located in proximity of the
C-terminal helix, providing additional membrane-binding inter-
actions. One of these loops (residues 99^112) also functions in
opening and closing the MAO B active site cavity, which sug-
gests that the membrane may have a role in controlling sub-
strate binding.
, 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Eukaryotic monoamine oxidases (MAOs) catalyze the oxi-
dative deamination of primary and secondary aromatic
amines to imines, with concomitant reduction of oxygen to
hydrogen peroxide. In mammals two isoforms of this enzyme
have been identi¢ed as separate gene products, namely MAO
A and MAO B [1,2]. The physiological roles of MAOs are
related to the nature of their substrates. MAO A preferentially
oxidizes the neurotransmitter serotonin and exhibits overlap-
ping speci¢city with MAO B with adrenaline and dopamine.
MAO B is most active with other arylalkylamines such as
benzylamine, thus participating in the metabolism of exoge-
nous amines to prevent their possible function as false neuro-
transmitters. MAOs are involved in depression and in a num-
ber of neurodegenerative disorders such as Parkinson’s disease
and, therefore, are well-known targets for drug treatment of
these pathological conditions [3].
MAO A and MAO B are integral outer mitochondrial
membrane proteins [4]. Controlled proteolysis experiments
suggest that these enzymes may be distributed in di¡erent
orientations with respect to the membrane [5], although the
exact orientation for each isozyme remains to be ¢rmly estab-
lished. Although the signals that mediate targeting and inser-
tion of proteins into the outer mitochondrial membrane are
poorly understood, MAOs have common features with other
outer membrane mitochondrial proteins in that they have a
C-terminal non-cleavable targeting signal sequence which is
inserted into the membrane without proteolytic maturation
[6,7]. Sequence analysis predicts that the C-terminal 32 amino
acids (residues 489^520) form a transmembrane helix that
anchors the protein to the mitochondrial membrane. Trunca-
tions at di¡erent levels of the C-terminus a¡ect MAO B cata-
lytic activity, which implies that this portion of the protein is
important not only for membrane binding but also for enzyme
functionality and stability [8].
2. The three-dimensional structure of human MAO B
We initially described the structure of human MAO B at
3.0 AA resolution (PDB code 1GOS) [9]. The structure was
solved by X-ray crystallography using two crystal forms
that were obtained under the same conditions with two dif-
ferent detergents (lauryldimethylamine oxide and Zwittergent
3^12). Crystal quality dramatically improved when the en-
zyme was crystallized in the presence of di¡erent competitive
inhibitors. High resolution X-ray data (up to 1.7 AA ) were
collected and the coordinates of MAO B have been re¢ned
in a number of complexes with reversible and irreversible inhib-
itors (PDB codes 1OJA, 1OJB, 1OJC, 1OJD, and 1OJ9) [10].
The crystal structure of MAO B (520 amino acids) reveals a
dimeric enzyme (Fig. 1A). Each monomer consists of a sol-
vent-exposed globular structure (residues 1^488) anchored to
the membrane by a C-terminal hydrophobic K-helix (residues
489^500). The solvent-exposed part of the protein resembles
the structure of other £avin-dependent enzymes consisting of
an FAD-binding domain (colored in blue in Fig. 1A) and a
substrate-binding domain (in red in Fig. 1A). The latter do-
main accommodates a 700 AA 3 large cavity that originates
from one side of the protein surface and extends deep into
the protein, reaching the re face of the £avin cofactor. Anal-
ysis of the structure in complex with reversible and irreversible
inhibitors revealed that this cavity forms the active site of this
enzyme [10]. The MAO B dimer is identical in both crystal
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forms and involves a signi¢cant fraction of the protein surface
(15% of the monomer accessible surface). These structural
data predict that MAO B exists as a dimer in its mem-
brane-bound form. Current kinetic data show the respective
active sites are independent which is consistent with the en-
trances to the two active site cavities being located opposite
with respect to the dimer interface (Fig. 1A).
In each MAO B monomer an extended loop (residues 461^
488) originates from the FAD-binding domain and connects
the main body of the protein to the C-terminal K-helix (in
green in Fig. 1A). The conformation of this loop is stabilized
by a number of interactions with the amino acid side chains of
both substrate- and cofactor-binding domains. This loop leads
to the C-terminal hydrophobic helix that departs perpendicu-
larly from the base of each monomer. Most remarkably, the
helical axis is parallel to the dimer two-fold axis (Fig. 1A).
This suggests that the dimer is oriented with its axis perpen-
dicular to the plane of the membrane, with the C-terminal
helices rooted into the bilayer. This model is in agreement
with hydropathy plots (MPEx, http://blanco.biomol.uci.edu/
mpex) that identify residues 489^515 with signi¢cant free en-
ergy values for transmembrane segments. The side chain of
Arg494 is properly oriented to establish electrostatic interac-
tions with the polar head groups of the membrane phospho-
lipids (Fig. 1B). In the dimeric structure, the transmembrane
helices are too far from each other to establish any direct
interactions.
The MAO B substrate-binding domain bears some solvent-
exposed hydrophobic sites (Pro109^Ile110, Trp157) that are in
close proximity to the C-terminal helix and therefore are likely
to be involved in membrane binding (Fig. 1B). Indeed, it has
been shown that truncations of the C-terminal tail (residues
461^520) at di¡erent levels do not prevent a partial binding of
MAO B to the membrane [8]. These data agree with hydro-
pathy plots that identify additional segments with free energy
values compatible with these polypeptide stretches being at
the bilayer interface. These hydrophobic patches may help
to create a more rigid orientation of the protein to the mem-
brane surface.
The full-length MAO B (520 amino acids) was used for
crystallization in the presence of di¡erent inhibitors. In all
structures the electron density is interrupted at Thr500, imply-
ing that residues 501^520 are disordered in the crystals. In the
outer mitochondrial membrane, the disordered residues are
predicted to extend the C-terminal helix such that it can
span the membrane, with the last ¢ve residues (516^520) being
exposed on the opposite side with respect to the main body of
the protein (Fig. 2, right panel). However, another possibility
is that the last 20 residues, rather than extending the trans-
membrane helix, may turn back to position the C-terminus on
the same side of the outer membrane surface where the main
body of the MAO B dimer is located (Fig. 2, left panel). So
far, no experimental evidence is available to distinguish be-
tween these two models. Interestingly, a small two-residue
deletion with respect to MAO B (deletion of residues 501^
502 in MAO B) is observed in the sequence of the highly
homologous MAO A isozyme. A chimera of MAO B in which
the C-terminus (residues 393^520) was replaced with the
MAO A C-terminus (residues 402^527) shows no catalytic
activity [11] which suggests the MAO A C-terminus cannot
function in protein folding and/or membrane insertion in the
place of the MAO B sequence. These di¡erences suggest that
the regular path of the C-terminal helix may be interrupted at
residue 500.
The relationship between the mitochondrial outer mem-
brane localization and physiological roles of MAOs remains
to be elucidated. Other amine oxidases such as polyamine
Fig. 1. Three-dimensional structure of human MAO B. A: Structure
of MAO B dimer bound to the phospholipid bilayer. Each mono-
mer has a two-domain overall topology, consisting of the FAD-
binding domain in blue and the substrate-binding domain in red.
The amino- and carboxy-termini of each monomer are highlighted
as ‘N’ and ‘C’, respectively. The FAD cofactor is represented in yel-
low ball-and-stick. The C-terminal membrane-binding region is de-
picted in green. In each monomer the active site cavity is colored in
light blue. B: The C-terminal transmembrane helix and the neigh-
boring apolar sites involved in membrane binding. The secondary
structures are colored as in A. Residue side chains are in ball-and-
stick representation, with carbon atoms represented in black, nitro-
gens in blue, oxygens in red. The gray line is indicative of the upper
boundary of the membrane but it is not intended to represent the
exact depth of protein insertion into the membrane.
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oxidase are not membrane proteins [12]. The crystal structure
shows that the active site of MAO B is located in the globular
part of the protein. This raises the question of why MAOs are
membrane-bound. In the MAO B dimer, the substrate-bind-
ing site of each monomer faces the membrane surface and
partly interacts with it (Fig. 1A). In particular, loop 99^112,
which functions as a gate to the active site cavity, is expected
to be partly embedded in the membrane (Fig. 1B). The mem-
brane may have a role in controlling the function of this loop
in gating the active site. In this regard it is important to point
out that the protonated amino group of MAO B substrates
may be attracted to the membrane surface and to the catalytic
site by electrostatic interactions with the negatively charged
phosphate head groups. These considerations would imply
that the membrane may have a role in increasing the local
substrate concentration at the active site of MAO by electro-
static interactions.
3. Comparison with other monotopic membrane proteins
MAOs are classi¢ed as integral membrane proteins because
digestion of membrane phospholipids is needed for detergent
extraction of the protein from its membrane environment [13].
The high resolution crystal structure of human MAO B pro-
vides the basis for a model consisting of a soluble globular
core anchored to the membrane through a hydrophobic C-ter-
minal helix that protrudes perpendicularly from the base of
the structure. To date no other structures with similar mem-
brane-binding domains have been described. Among mono-
topic membrane proteins the structures of prostaglandin H2
synthase and of squalene cyclase have been solved. Prosta-
glandin H2 synthase (also known as cyclooxygenase) is char-
acterized by three amphipathic helices that lie approximately
in a plane at the base of the structure, creating an extensive
hydrophobic surface that interacts with the membrane hydro-
phobic core [14,15]. The squalene cyclase structure shows a
very similar architecture with an K-helix together with three
loops forming a large non-polar plateau encircled by a ring of
positively charged amino acids [16,17]. In MAO B the C-ter-
minal helix is perpendicular to the plane of the membrane and
hydrophobic amino acids are distributed along the helix, with
only one positively charged residue, Arg494, whose side chain
points towards the membrane polar heads.
Another monotopic membrane protein whose structure has
been recently described is fatty acid amide hydrolase [18],
which is predicted to have an N-terminal transmembrane do-
main. The structure of a truncated form of this protein (lack-
ing the N-terminal portion) reveals a dimeric enzyme. Two
K-helices at the base of each monomer could interact with
the membrane in a manner similar to what is found in pros-
taglandin H2 synthase and squalene cyclase. At opposite sides
of the dimer two long N-terminal helices run parallel to the
molecular two-fold axis, with each N-terminus situated in a
position appropriate to be preceded by the predicted trans-
membrane helix in the intact enzyme. This putative N-termi-
nal transmembrane helix could reinforce the membrane inter-
actions of the two helices at the base of the protein.
4. Conclusions
Few structures of monotopic membrane proteins are
known. The MAO B structure reveals the presence of a C-
terminal hydrophobic K-helix that is oriented properly for
transmembrane insertion, while the other monotopic struc-
tures are characterized by amphipathic helices that face the
base of the protein on one side and the membrane on the
other. In this respect, MAO B is presently unique among
the structurally characterized monotopic membrane proteins.
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Fig. 2. Proposed hypotheses for the structure of the C-terminal tail (residues 500^520). MAO B dimer is represented as in Fig. 1A. The gray
square represents the membrane, while the two possible conformations of the C-terminal part are depicted as gray cylinders. In the right panel
the helix is suggested to span the entire bilayer; in the left panel another hypothesis is proposed in which the helix is interrupted, with the
polypeptide chain turning back with the C-terminus positioned on the same side of the membrane with respect to the main body of the protein.
All pictures have been produced with the programs Molscript [19] and Raster3D [20].
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